You are here: Industry Insights > Imbruvica

News List

AbbVie's 2Q Revenue up 34% contractpharma
August 02, 2021
New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL pharmatimes
June 17, 2021
Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study.
Chemotherapy-free combination shows potential in lymphocytic leukaemia trial europeanpharmaceuticalreview
June 09, 2021
Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.
Imbruvica®-based regimens induce lasting remissions in leukaemia trials europeanpharmaceuticalreview
May 21, 2021
Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.
NATCO gets tentative US FDA approval for Ibrutinib tablets expresspharma
April 12, 2021
NATCO feels that it is eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form of the product at the time of launch.
Calquence tops Imbruvica in chronic lymphocytic leukaemia study pharmatimes
January 26, 2021
AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) hit the primary endpoint in a Phase III study in chronic lymphocytic leukaemia (CLL).
Bavencio, Imbruvica among latest SMC decisions pharmatimes
October 15, 2020
In its latest guidance, the Scottish Medicines Consortium (SMC) has accepted eight new medicines for use by NHS Scotland.
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab pharmaceutical-business-review
September 23, 2020
Janssen Pharmaceutical, part of Johnson & Johnson, has secured approval from the European Commission (EC) for expanded use of Imbruvica (ibrutinib) in combination with rituximab for previously untreated adult patients with chronic lymphocytic leukaemia.
EU expands scope of Imbruvica to include untreated CLL patients pharmatimes
September 17, 2020
The European Commission (EC) has expanded the marketing authorisation for Janssen's Imbruvica (ibrutinib) to include treatment naïve patients with chronic lymphocytic leukaemia (CLL).
Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL expresspharma
September 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved a variation to the marketing authorisation for IMBRUVICA (ibrutinib) ...

Previous page 1 2 3 Next page